Main Article Content


Background: Comprising 14% of all cancer, lung cancer is the main cause of cancer-related mortality worldwide. Previous studies showed various findings regarding the survival rate of lung cancer, and factors significantly correlated with survival rate in lung cancer patients.

Aim: This research aims to identify the profile and survival rate of lung cancer patients receiving chemotherapy in Saiful Anwar General Hospital from 2018 to 2020.

Methods: This cohort retrospective study used medical records of patients diagnosed with lung cancer who underwent chemotherapy from 2018 to 2020. Data analysis was done using the Mantel Cox log rank test. Survival data shown as progression free survival (PFS) and overall survival (OS) were shown using Kaplan-Meier curves.

Results: Subjects were largely male (73,2%). Adenocarcinoma is the most often type of lung cancer found (59,8%) with wild type EGFR mutation being the most prevalent (20,6%). Carboplatin – Paclitaxel is the most widely used chemotherapy regimen (54,6%). Survival analysis showed a significant correlation between age, OS, and PFS (p < 0,05)

Conclusion: Various factors such as gender, cancer cell type, EGFR mutation, and chemotherapy regimen were not found to be related to survival rate in lung cancer patients. A significant correlation between age and survival rate showed potential in utilizing age as a predictor of survival rate in lung cancer patients.

Article Details

How to Cite
Pratiwi, S. D., Setyawan, U. A., Falyani, S. A., Permatasari, A. P., Santosa, A., Febriawati, J., Prasetyo, K. W., & Yokanan. (2024). Survival Analysis of Lung Cancer Patients at Dr. Saiful Anwar Hospital. Jurnal Klinik Dan Riset Kesehatan, 3(3), 153-160.


1. Barta JA, Powell CA, Wisnivesky JP. Global Epi-demiology of Lung Cancer. Annals of Global Health. 2019;85(1):8.
2. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Con-temp Oncol (Pozn). 2021;25(1):45–52.
3. KPKN. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. 2017;
4. Pratiwi SD. Profil Tumor Paru tahun 2017 pada Instalasi Rawat Inap 1 RSUD dr. Saiful Anwar Malang. 2020;
5. ÖNAL Ö, KOÇER M, EROĞLU HN, YILMAZ SD, EROĞLU İ, KARADOĞAN D. Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer. Turk J Med Sci. 2020 Dec 17;50(8):1838–50.
6. Liu C, Ma M, Zhou X, Zhang Z, Guo Y. Multivari-ate analysis of prognostic factors in patients with lung cancer. Frontiers in Oncology [Inter-net]. 2023 [cited 2023 Jul 13];13. Available from:
7. Torrente M, Sousa PA, Guerreiro GR, Franco F, Hernández R, Parejo C, et al. Clinical factors in-fluencing long-term survival in a real-life co-hort of early stage non-small-cell lung cancer patients in Spain. Frontiers in Oncology [Inter-net]. 2023 [cited 2023 Jul 13];13. Available from:
8. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
9. Hong H, Wang Q, Li J, Liu H, Meng X, Zhang H. Aging, Cancer and Immunity. J Cancer. 2019 Jun 2;10(13):3021–7.
10. Zannah SJ, Murti IS, Sulistiawati S. Hubungan Usia dengan Stadium Saat Diagnosis Penderita Kanker Kolorektal di RSUD Abdul Wahab Sjah-ranie Samarinda: Relationship of Age and Sta-dium when Diagnosed of Cholorectal Cancer at RSUD Abdul Wahab Sjahranie Samarinda. Jurnal Sains dan Kesehatan. 2021 Oct 31;3(5):701–5.
11. Ahmed T, Lycan T, Dothard A, Ehrlichman P, Ruiz J, Farris M, et al. Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non—Small-Cell Lung Cancer. Clin Lung Cancer. 2020 Jul;21(4):e286–93.
12. McLean AEB, Barnes DJ, Troy LK. Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Inva-sive and Personalised Medicine. J Clin Med. 2018 Jun 29;7(7):163.
13. Magios N, Bozorgmehr F, Volckmar AL, Kazdal D, Kirchner M, Herth FJ, et al. Real-world im-plementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther Adv Med Oncol. 2021;13:1758835921996509.
14. Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, et al. Efficacy of plati-num agents for stage III non-small-cell lung cancer following platinum-based chemoradio-therapy: a retrospective study. BMC Cancer. 2022 Mar 29;22(1):342.